NEJM Group

CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

March 28th, 2014

ACC.14 Headquarters

wpengine

CardioExchange is dedicated to bringing you the latest from ACC.14. Check out our coverage of the conference ─ and some of the great debates these posts have sparked ─ then tell us what you think!

News:

  • No Benefit Found in First Real Test of Renal Denervation
  • Survival Advantage for TAVR Over Surgery in High-Risk Patients
  • First TAVR Comparison Trial Favors Sapien XT Over CoreValve
  • MADIT-CRT Long-Term Follow-Up Shows Survival Benefit with CRT-D
  • High-Sensitivity Troponin Test Could Identify Low-Risk Chest Pain Patients in the ED
  • Aspirin and Clonidine Fail to Help Surgery Patients
  • Novartis Trial Was Stopped Early Because of a Significant Drop in Cardiovascular Mortality

Analysis:

  • Negative Findings on Renal Denervation for Hypertension: Sweet SYMPLICITY?
  • TAVR: Are You Impressed Now?
  • Long-Term Follow-Up from MADIT-CRT: Guideline Implications
  • Are We Equipped to Make a CHOICE Between TAVR Devices?

Follow our Fellows:

  • Changing My Priorities for ACC.14
  • Ideals Lost, But Not Stolen
  • Are Digital Conferences the Way of the Future?
  • Taking Patient-Centerdness to the Next Level at ACC.14
  • Stage Set for Phase IV Trials of PCSK9 Inhibition
  • Master of all Trades

Categories: General


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.

  • Search the Archive

  • Archives by Date

  • RSS NEJM — Recent Cardiology Articles

    • Intention to Treat — Season 2: The Race Equation: BiDil — The Story of the Black Pill — ITT Episode 2.5 June 4, 2026
      How did a drug for congestive heart failure get approved and marketed for Black people only?
    • Left Atrial Appendage Closure — Should Recommendations Be Expanded? June 4, 2026
      Owing to the fact that most thromboembolic complications that are attributed to atrial fibrillation originate in the left atrial appendage,1 therapies targeting the anatomical structure that might spare systemic harms are theoretically attractive. Randomized trials of left atrial appendage closure previously garnered an American College of Cardiology–American Heart...
    • Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation June 4, 2026
      In patients with atrial fibrillation, left atrial appendage closure was noninferior to NOACs in an analysis of death from cardiovascular causes, stroke, or systemic embolism and was superior for non–procedure-related bleeding.
    • Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting June 3, 2026
      Since Dr. Phillip Hench reported on the efficacy of glucocorticoids for rheumatoid arthritis in 1949, glucocorticoids have saved many lives and have offered relief to countless patients. Glucocorticoids have been used as the mainstay of treatment for many immune-mediated inflammatory diseases, including polymyalgia rheumatica and giant-cell arteritis (GCA), owing to...
    • Science behind the Study: Remuscularizing the Failing Human Heart May 28, 2026
      The author describes the scientific foundations of a phase 1–2 study of stem-cell–derived ventricular assist tissue transplanted onto the epicardial surface of failing human hearts.
  • Tag Cloud

    • ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women
NEJM Group

Copyright © 2026 Massachusetts Medical Society. All rights reserved.

The content of this site is intended for health care professionals. Copyright | Terms | Privacy Policy |